Method of producing guanine derivatives or their acid=additive salts suitable for pharmacy

专利摘要:
The present invention relates to certain amino acid esters of the purine nucleoside acyclovir, pharmaceutically acceptable salts thereof and their use in the treatment and prophylaxis of herpes virus infections. The invention also includes pharmaceutical formulations and processes for the preparation of such compounds.
公开号:SU1634138A3
申请号:SU884356404
申请日:1988-08-12
公开日:1991-03-07
发明作者:Энтони Креницки Томас；Мари Бьючэмп Лилиа
申请人:Дзе Веллкам Фаундейшн Лимитед (Фирма)；
IPC主号:

专利说明:

(NH2) N-C C-N CH-N-CHf-Q- (CH 2b-Q-C (OVCH (R) -NH
2
where R is CH (СНЭ) 2 or СН (СН,) is СНг-СН3, or their acid-additive pharmaceutically acceptable salts, which have antiviral effect, which can be used in medicine. The goal is to create new, more active and less toxic substances of the indicated class Purpose The invention relates to a method for producing new guanine derivatives having valuable antiviral properties that can be used in medicine.
The purpose of the invention is the creation of new guanine derivatives possessing a higher antiviral active product as a base or transferring it to a salt by the action of an acid (better than HC1) o New compounds exhibit antibacterial activity against the lichen bubble virus: concentration causing 50% inhibition virus development, 0.84 and 3.8 microns versus 0.08-0.1 microns for acyclovir, have a high bioavailability; the amount of administered dose (in urine) in the form of acyclovir is 63% and 50% against 15% for acyclovir. 1 з „p f-ly, 1 tabl„
J
(L
about with
four
with oo
due to higher bioavailability and lower toxicity.
Example I „2-Ј (2-Amino-1,6-dihydro-6-oxo-9H-purin-9-yl) methoxyDethyl-b-valinate,
a) 2-Ј (2-Amino-1, L-dihydro-6-oxo-9H-purin-9-yl) methoxy1-ethyl-LYG (oenyloxy) carbonic | -1, -valinate.

cm
Suspension of acyclovir (2.0 g) in dry dimethylformamide (DMF) 150 ml is heated to 60 ° C, the result is a colorless solution "To the warm solution add 3,012 g of carboxybenzyl-L-valine (CBZ-L-valine) 154 mg 4-dimethylaminopyridium (DMA11), 2,998i dicyclohexylcarbodiimide (DHA) 0 The pale yellow solution is allowed to cool to room temperature and stir for a night. After 30 minutes, a white precipitate is observed. -L- 15 valine, DMAP and DHA and turbid suspension is stirred for d vuh days at room temperature
After that, the suspension is filtered. To obtain 1.418 g of a white solid 20, the Colorless filtrate is concentrated to give a yellowish oily liquid, which is purified by chromatography on silica gel. Elution is carried out with mixtures of methanol and dichloromethane a different composition (0-15%) o The result is 3.751 g of the target compound (yield 91.1%) as a white solid, Q
c) 2-Ј (2-Amino-1,6-dihydro-6-oxo-9H-purin 9-yl) methoxy1-ethyl-b-valinat
A mixture of 5.0 g of 2-Ј (2-; 1mino-1,6-di-hydro-6 oxo-9H-purin-9-yl) methoxy - ethg-N- (benzyloxy) carbonyl | -1 valinate, 2 g of a 5% palladium catalyst on coal (50% water) and 50 ml of DMF are shaken in a Parr apparatus at a hydrogen pressure of 40 pounds per quoyant for 3 hours. The reaction mixture of the filter is rubbed through a layer of celite and evaporated in vacuo, obtaining an oily liquid. Crystallization is carried out from a mixture of water and ethanol in a 1: 3 volumetric co-i ratio.) After recrystallization, 1.5 g of the title compound is obtained.
Calculated,%: C 48.14; H 6.22; N 25.91.
Found,%: C 47.84; H 6.26; N 25.75s
PRI mme R 2. 2- (2-Amino-1, 6-dihydro-6-oxo-9H-purin-9-yl) methoxy-Dethyl-b-valinate hydrochloride monohydrate „
a) 2- Ј (2-Amino-1,6-dihydro-1,6-o cp-9H-purin-9-yl) methoxy-ethyl-H- Ј (benzyloxy) carbon NG b-valinat,
Q 5
0 5 Q
l i
0
2.0 g of a suspension of acyclovir in dry DMF (150 ml) is heated to 60 ° C, resulting in a colorless solution "To the warm solution are added 3,012 g of CBZ-L-valinat, 154 mg of DMAP, and 2.998 g of DHA. The yellowish solution is allowed to cool to room temperature and stirred overnight. After 30 minutes, a white precipitate is observed. The indicated mixture of CBZ-L-valine, DMAP and DHA is again added to the reaction mixture and the turbid suspension is stirred at room temperature for two days. which is filtered, yielding 1.418 g of a white solid. The colorless filtrate is concentrated to give a yellowish oily liquid, which is purified by chromatography on silica gel using mixtures of methanol and dichloromethane of different composition (0-15%) as eluent. The result is 3.751 g of the desired compound (92.1%) as white solid matter.
c) 2-Ј (2-Amino-1,6-dihydro-b-oxo-9H-purin-9-yl) methoxy-ethyl-b-valinate hydrochloride monohydrate
A mixture of 3.730 g of 2- (2-amino-1, 6-di-hydro-6-oxo-9I-purine 9-yl) methoxy-ethyl-Nl benzyloxy) carbonyl JL-valinata, 3/7 mg 5% - a palladium carbon catalyst, 100 ml of methanol, 100 ml of THF and 18 ml of 0.5 M hydrochloric acid are shaken in a Parr apparatus at a hydrogen pressure of 50 psig for days. The reaction mixture is then filtered through a pad of celite and concentrated to a white solid, which is recrystallized from a mixture of water and ethanol.
The result is 1.762 g (60.0%) of the title compound as a white powder, Topl — 150 ° C (solid shrinkage) with a gradual transition into an oily liquid and decomposition with foaming at 195 C,
Calculated%: C 4l, 22j H 6.15; N 22.19; C1 9.36.
Found,%: C 41.09; H 6.10; N 22.12; C1 9.28 „
EXAMPLE 3 3 2- (2-Amino-1,6-dihydro-6-oxo-9H-purin-9-yl) methoxy-pyethyl-B-valinate hydrochloride monohydrate.
stirring at room temperature for another 7 days. The mixture is then filtered and the clear filtrate is concentrated in vacuo to give a semi-solid residue. When elution from the residue on silica gel 60 (EM, 230-400 mesh. 8.5) 44 cm) with a mixture of 2.5-5% methanol and methylene chloride, 0 is obtained. 8 g (45%) of 2- Ј (2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl) methoxy ethyl-YH-G (benzyloxy) carbonyl Nata as a white solid, mp. 155-157 ° C
UV (MeOH), nm: ftmac: 255 (Ј17700) A $ L 279 (9800) MK1M 230 (6100)
NMR (200 MHz, Me2SOdfe), Y: 0.73 - 0.80 (m, 6H); 1.13-1.33 (m, 2H); 1.66-1.70 (m, 1H); 3.64 (t, 2H); 3.92 (t, 1H); 4.16 (m, 2H); 5.00 (s, 2H); 5.32 (s, 2H); 6.47 (width s, 2H); 7.33 (s, 5H), 7.65 (d, J-8 Hz, 1H); 7.78
(s, 1H); 10.59 (broad co, 1H)
Mace spectrometry (C1 / (L; 70 C, M / Z: 473 (1.0% M + 1); 347 (23.2, M-125); 225 (100.0 M-247).
MS °° (6 n
Thin layer chromatography: single spot on silica gel using 10% MeOH / SNgC12, RЈ 0.38 as mobile phase, HPLC: one peak on Supelco LCg using 50% MeOH / H O as the mobile phase; 100% K 7,
Calculated,%: C 53.87; H 6.16; N 17.13 C22H N606-HZ0
Found,%: C 53.94; H 6.20; N 17.04.
c) 2-G (2-Amino-1,6-dihydrr-b-oxo-9H-purin-9-yl) methoxy | ethyl b-isoleucine hydrochloride
A solution of 1.1 g (2.2 mmol) of 2- (2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl) methoxy ethyl-H- бенз (benzyloxy) carbonyl-l-b β-isoleucine in 50 ml of a mixture of methanol and THF (1: 1) is treated with 5 ml of 0.5 n. hydrochloric acid and 0.30 g of 5% palladium on charcoal. The mixture is hydrogenated in a Parr hydrogenator at a pressure of 50 psig for 11 hours, filtered through a pad of celite, and the filtrate is concentrated in vacuo. The result is
0.86 g (92%) of 2- (2-amino-1,6-dihydro-6-oxo-8H-purin-9-yl) methoxy ethyl-b- isoleucine hydrochloride as be5
five
0
0 5
0
five
logo of solid matter, tpl 180 - 182 ° С (strong softening at a temperature of / v 150 ° С) „
UV (MeOH); nm: das 254 (Ј13400);
ft5h 272 (9000); b mim 224 TSOOOO.
NMR (200 MHz,),: 0.77- 0.84 m.To (m. 6H); 1.13-1.37 (m, 2H); 1.82 (m. 1H); 3.73 (t, 2H); 3.87 (width s, t 1H); 4.14-4.40 (ms, 36 (s, 2H) ;, 6.70 (broad s, 2H); 7.97 (s, 1H); 8.46 (shooting, s, 3N); 10 , 87 (s, 1H) „
Mace spectrometry (C1 / CH4J 150 C) m / z: 367 (6.9% M + 29); 339 (100, M + 1); 225 (92.9, M-113) o
MV ° in ° + P, 15 ° (s-2.0, NOAc),
Thin layer chromatography: single spot on silica gel using 10% в as mobile phase, high resolution liquid chromatography one peak on Veisapack using 10% MeOH / HgO / 0.1% FjCCOOH as the mobile phase; 100% K 3.740
Calculated,%: C 42.81; H 6.70; N 19.84; C1 10.46,
C14H22N604 1.25 HCl 1.10 MeOH.X
 "0.2 NgO
Found,%: C 42.82; H 6.50; N 19.64; C1 10.46.
Antibacterial activity. Bovine lichen virus (HSV I) is analyzed in Vero cell monolayers in multi-cell plates. Compound activity is determined in experiments to reduce the number of platelets. In these experiments, the cell monolayer is infected with HSV I suspension, and then to prevent the virus from spreading in culture a layer of nutrient agarose in the form of a gel. Various amounts of the test compounds are then introduced into the nutrient agarose layer. The number of blood plates at each concentration is expressed as a percentage relative to the corresponding value in the control experiment, and according to the data obtained, a curve of the dependence of the degree of inhibition on the concentration is obtained. The concentration at which 50% inhibition (IC) is observed is measured using this curve. :
Compound by
for example:
1-40,84
53,8
51 s
a) 2-G (2-Amino-1,6-dihydro-6-oxo-9H-purin-9-yl) methoxy ethyl-N- (benzyl oxide) to arb onigG-0-in al inat „
A suspension of 1.00 g of acyclovir in 80 ml of dry DM is heated to 60 ° C to obtain a colorless solution. 1.70 g of CBZ-U-valine, 74 mg of DMAP and 1, BO of DHA are added to the warm solution. The clear solution is allowed to cool to room temperature and then stirred under nitrogen for 2 days. Thereafter, the indicated amounts of CBZ-D-valine, DMAP and DHA are added to the reaction mixture and the turbid suspension is stirred at room temperature for 2 days. After that, the suspension is filtered, the white solid precipitate is separated. The colorless filtrate is concentrated, the residue is dissolved in a mixture of methanol and dichloromethane, and the resulting solution is chromatographed on silica gel using 10% methanol in dichloromethane as eluent. 1.10 g (52% of the desired compound as a white solid) are obtained. substances, t „pl, 155-158 С0
Calculated,%: C 52 „05; H 6.01; N 17.34s
Found,%: C 52.02; H 5.98;
N 17.320
c) 2- (2-Amino-1,6-dihydro-b-oxo-9H-purin-9-yl) methoxyP-ethyl-0-valinate
monohydrate hydrochloride
A mixture of 0.94 g of 2-Ј (2-Amino-1,6-dihyd ro-6-oxo-9H-purin-9-yl) methoxy ethyl-N- Ј (benzyloxy) carbonyl-P-valinate, 200 mg 5 % Pd catalyst on carbon, 25 mg of methanol, 25 ml of THF and 4.5 ml of 0.5 M hydrochloric acid
Shake in a Parr apparatus at 44 psi hydrogen pressure for 4 h. After this, the reaction mixture is filtered through a microporous membrane and the filtrate is concentrated. As a result, the target compound is obtained in the form of a white-white substance, Tplo 185-188 ° C.
Calculated,%: C 40.47; H 6.18; N 21.37; C1 10.82.
Found,%: C 40.62; H 5.98; N 21.20; C1 10.91o
PRI me R 4. 2-Ј (2-Amino-1,6-dihydro-6-oxo-9H-purin-9-yl) methoxy ethyl-DL- in alium at hydrochloride monohydrate,
a) 2- Ј (2-Amino-1,6-dihydro-6-oxo-9H-purin-9-yl) methoxy ethyl-L- Hbenzyloxy) carbonyl —Sh, -valynate.
86
A suspension of 2,000 g of acyclovir in 150 ml of dry DM is heated to a colorless solution. 3,012 g of CBZ-DL-valine, 154 mg of DMAP and 2.998 g of DHA are added to the warm solution. The solution is allowed to cool to room temperature and stirred overnight. Thereafter, the indicated amounts of CBZ-DL-valine, DMAP and DHA are added to the reaction mixture and the suspension is stirred at room temperature for 2 days. Then it is filtered, the white solid is separated, and the filtrate is concentrated and purified by chromatography on silica gel using as eluent, mixtures of methanol and dichloromethane in various ratios (0-15%). The result is the target compound
c) 2- Ј (2-Amino-1,6-dihydro-b-oxo-9H-purin-9-yl) methoxy-ethyl-Bb-valinate hydrochloride monohydrate „
A mixture of 3.730 g of 2-Ј (2-amino-1,6-dihyd ro-6-oxo-9H-purin-9-yl) methoxy - ethyl-N- (benzyloxy) carbon G {i-valinate, 377 mg A 5% palladium on carbon catalyst, 100 ml of methanol, 100 ml of THF and 18 ml of 0.5 M hydrochloric acid are shaken in a Parr apparatus at a hydrogen pressure of 50 psi for days. The reaction mixture is then filtered through a pad of celite and concentrated to a solid, which is then recrystallized from a mixture of water and ethanol. The result is a target compound.
II p and mep 5 about 2-Ј (2-amino-1, 6-di-hydro-6-oxo-9H-purin-9-yl) methoxy | - ethyl-b-isoleucate hydrochloride
a) 2- Ј (2-Amino-1, b-dihydro-6-oxo-9H-purin-9-yl) methoxy | ethyl N- (benzyl oxy) carbon-G-L-from oleucine.
A mixture of 1.0 g (4.4 mmol) of acyclovir, 74 mg (0.6 mmol) of 4-dimethylaminopiridine, 1.6 g (8.0 mmol) of 1,3-dicyclohexylcarbodiimide, 1.8 g ( 6.6 mmol) of M-carbobeneoxy-b-isoleucine and 0.3 g of molecular sieve Dauson type 3A in 80 ml of dry dimethylformamide are stirred at room temperature under a nitrogen atmosphere. After 4 days, another 1.6 g (8.0 mmol) of 1,3-dicyclohexylcarbodimimide and 1.8 g (6.6 mmol) of N-carboxy-benzoxy-b-isoleucine are added to it and continue
Acyclovir
(ACV) 0.08-0.1
Determination of oral bioavailability. Long Evans rats were administered through a stomach tube administered through the nose, test compounds were administered at doses equivalent to 25 mg / kg of acyclovir. Urine was collected in 24 and 48 hours and analyzed after ultrafiltration using high-pressure liquid chromatography. Oral bioavailability of the compounds was expressed in number ( as a percentage of the administered dose) of the compound detected in the urine (in the form of acyclovir), 1
1-463
550
ACV15
Glycyl
ACV30 air
OS-Alanilo
ACTV34
Determination of growth inhibition of mammalian cells.
The ability of the tested compounds to inhibit the growth of D98 (human) and L (mice) cells was determined by the number of cells after holding the standard number of cells in solutions of a compound of different concentrations for three days. The number of cells found was compared with the number obtained in the absence of a compound The number of cells was determined either by direct counting and subsequent trypsinization of the monolayer, or by spectrophotometric determination of the amount of dye absorbed by the cells. Both methods my results.
The concentration of the compound at which 50% inhibition was observed (1Cy0) compared to the control experiment was calculated either directly by interpolation from the graph of the dependence of the logarithm of the concentration of the compound on the percentage of the control value, or from a computer program in which the analysis is performed using the same algorithm ,, In these calculations data were used within 20 - 80% of control values.
The research results are given in the table.
ten
15

权利要求:
Claims (2)
[1]
Claims.
1 o A method for preparing guanine derivatives of general formula I
HE
I n
CX)
H2N N N-CH2OCH2CH2OCOCH / R / N
where R is a group —CH (CH3) 2 or a group
-CH (CH3) ,,
or their acid addition pharmaceutically acceptable salts, characterized in that 9- (2-hydroxyethoxymethyl) guanine
OH N
Yo H2N N N CH2OCH2CH2OH
interact with N-protected valine or isoleucine in the presence of dicyclohexylcarbodiimide: and, possibly, the base in an organic solvent followed by removal of the protective group and isolation of the desired product as a base or by salt conversion with an acid.
[2]
2. A process according to l 1, characterized in that hydrochloric acid is used as the acid. Priority featured:
15.08087 with R - the group -CH (SNE) 2.
11/05/87 with R - the tCH (CH3) SNgCNe group.

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1634138A3|1991-03-07|Method of producing guanine derivatives or their acid=additive salts suitable for pharmacy

---

CN109311851B|2021-08-10|Dihydro pyrimidinyl benzazepine carboxamide compounds

---

EP0303697B1|1997-10-01|Derivatives of physiologically active substance k-252

---

ES2467109T3|2014-06-11|Pyrrolo [2,3-d] pyrimidine compounds

---

Peterson et al.1991|Synthesis and biological evaluation of 4-purinylpyrrolidine nucleosides

---

RU2133749C1|1999-07-27|2-|metoxy-3-hydroxy- 1-propanyl-l-valinate, pharmaceutically acceptable salt thereof, method of preparing thereof, pharmaceutical composition and hydroxy and/or amino protected 2-| methoxy-3-hydroxy-1- propanyl-l-valinate

---

US20100022783A1|2010-01-28|Cyclohexanecarboxylic acid compound

---

EA007410B1|2006-10-27|N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors

---

US20100240667A1|2010-09-23|Crystalline forms of |-l-erythro-tetrahydrobiopterin dihydrochloride

---

WO2004106338A1|2004-12-09|Novel crystalline forms of valacyclovir hydrochloride

---

CA2671535A1|2008-06-26|Novel crystalline compound useful as glk activator

---

AU2015330554B2|2020-01-02|Crystal form of bisulfate of JAK inhibitor and preparation method therefor

---

EP3587420A1|2020-01-01|Tri-cycle compound and applications thereof

---

AU2011324253B2|2015-10-29|Hydrate of 1-{|-2-amino-4-[2,4-bis|-5,8-di- hydropyrido|-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate

---

DE19526163A1|1996-02-01|New ganciclovir mono:esters and intermediates

---

EP0408524B1|1995-11-08| acetamides as enhancers of learning and memory and pharmaceutical compositions comprising same

---

EP2411392B1|2014-02-26|Novel crystal forms of adefovir dipivoxil and processes for preparing the same

---

EP3322704B1|2019-11-27|Crystalline form of n-[|methyl]-2-|-yl)-6-methyl-4-quinazolinamine for the treatment of respiratory syncytial virus | infections

---

RU2536685C2|2014-12-27|Pharmaceutically acceptable thymodepressin salts and method of obtaining thereof

---

EP2896623A1|2015-07-22|CRYSTAL OF N-[2-|-2-CYANOPYRROLIDIN-1-YL]-2- OXOETHYL}AMINO)-2-METHYLPROPYL]-2-METHYLPYRAZOLO[1,5-a]PYRIMIDINE-6-CARBOXAMIDE

---

EP3590944A1|2020-01-08|Azetidine derivative

---

CN104974221B|2020-10-23|Dipeptide and tripeptide proteasome inhibitors and preparation method and pharmaceutical application thereof

---

ES2879294T3|2021-11-22|Polymorphic forms of Belinostat and processes for their preparation

---

EP0320988A2|1989-06-21|Epipodophyllotoxin glucoside 4'-acyl derivative

---

KR20190092440A|2019-08-07|Crystalline Form of Janus Kinase Inhibitor

同族专利:

---

公开号 | 公开日

---

IE882463L|1989-02-15|

---

IL87434A|1993-06-10|

---

NO883612L|1989-02-16|

---

LV5264A3|1993-10-10|

---

PT88261B|1995-03-01|

---

NL960001I2|1996-11-01|

---

NO1996015I1|1996-12-17|

---

AP8800099A0|1988-08-01|

---

FI883757A|1989-02-16|

---

DE3855333D1|1996-07-04|

---

PL274215A1|1990-02-19|

---

EP0308065A3|1989-09-27|

---

CN1033701C|1997-01-01|

---

DK451388D0|1988-08-12|

---

EP0596542A1|1994-05-11|

---

AU2097888A|1989-02-16|

---

NO167805B|1991-09-02|

---

IL87434D0|1989-01-31|

---

GR3020372T3|1996-09-30|

---

NZ225809A|1991-07-26|

---

FI89713B|1993-07-30|

---

DK82694A|1994-07-08|

---

EP0596542B1|1996-05-29|

---

DK451388A|1989-02-16|

---

AP55A|1989-09-26|

---

AP160A|1991-11-18|

---

FI89713C|1993-11-10|

---

DK170045B1|1995-05-08|

---

HUT47935A|1989-04-28|

---

HU201071B|1990-09-28|

---

NO167805C|1991-12-11|

---

CS8805594A2|1990-06-13|

---

AU612393B2|1991-07-11|

---

MY103760A|1993-09-30|

---

FI883757A0|1988-08-12|

---

JPH03115284A|1991-05-16|

---

SG26346G|1995-09-01|

---

JPH0662623B2|1994-08-17|

---

PT88261A|1989-06-30|

---

JPH07113025B2|1995-12-06|

---

NL960001I1|1996-03-01|

---

CY1833A|1995-12-01|

---

MC1968A1|1989-09-29|

---

LU88746I2|1996-10-04|

---

CN1032538A|1989-04-26|

---

AT138660T|1996-06-15|

---

EP0308065B1|1995-01-04|

---

NO883612D0|1988-08-12|

---

AU612393C|2006-08-17|

---

DE3855333T2|1996-12-05|

---

SA1348B1|2006-10-02|

---

CS276903B6|1992-09-16|

---

KR960002849B1|1996-02-27|

---

MX9203418A|1992-07-01|

---

PL158285B1|1992-08-31|

---

DK170803B1|1996-01-22|

---

ES2087639T3|1996-07-16|

---

JPS6468373A|1989-03-14|

---

KR960004940B1|1996-04-18|

---

IE65551B1|1995-11-01|

---

EP0308065A2|1989-03-22|

---

KR890003761A|1989-04-17|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

RU2750867C1|2020-05-18|2021-07-05|Александр Сергеевич Самойлов|Guanine derivatives|NL8202626A|1982-06-29|1984-01-16|Stichting Rega V Z W|DERIVATIVES OF 9- GUANINE.|

---

DE3627024A1|1985-09-24|1987-04-02|Hoechst Ag|2-AMINOPURINS SUBSTITUTED IN 6 AND 9 POSITIONS, THEIR USE, MEDICINAL PRODUCTS CONTAINING THESE PURINES AND METHOD FOR THE PRODUCTION OF THE PURINS|

---

DE3534774A1|1985-09-30|1987-04-02|Robugen Gmbh|Nucleoside-analogous compounds having antiviral activity, process for their preparation, and medicaments having antiviral action|

---

AP55A|1987-08-15|1989-09-26|The Wellcome Foundation Ltd|Therapeutic Acyclic Nucleosides|AP55A|1987-08-15|1989-09-26|The Wellcome Foundation Ltd|Therapeutic Acyclic Nucleosides|

---

GB8816760D0|1988-07-14|1988-08-17|Wellcome Found|Therapeutic compounds|

---

DE10299039I1|1988-12-19|2003-02-20|Wellcome Found|Antiviral pyrimidine and purine compounds Process for their preparation and pharmaceutical preparations containing them|

---

GB8829571D0|1988-12-19|1989-02-08|Wellcome Found|Antiviral compounds|

---

DE4008858A1|1990-03-20|1991-09-26|Hoechst Ag|New substd. purine antiviral cpds.|

---

EP0702682B1|1993-06-10|2001-03-14|Rolabo Sl|Process for the preparation of amino acid esters of nucleoside analogues|

---

GB9317146D0|1993-08-18|1993-10-06|Wellcome Found|Therapeutic combinations|

---

GB9320316D0|1993-10-01|1993-11-17|Smithkline Beecham Plc|Pharmaceuticals|

---

TW282470B|1993-11-18|1996-08-01|Ajinomoto Kk|

---

EP0665229B1|1994-02-01|1999-11-17|Ajinomoto Co., Inc.|Process for the production of nucleic acid base derivatives|

---

PE32296A1|1994-07-28|1996-08-07|Hoffmann La Roche|L-MONOVALINE ESTER DERIVED FROM 2-METOXI-1,3-PROPANDIOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS|

---

US5543414A|1994-07-28|1996-08-06|SyntexInc.|Achiral amino acid acyl esters of ganciclovir and its derivatives|

---

US5840891A|1994-07-28|1998-11-24|SyntexInc.|2- methoxy-1,3-propanediol derivative|

---

GB9501178D0|1995-01-20|1995-03-08|Wellcome Found|Guanine derivative|

---

GB9501127D0|1995-01-20|1995-03-08|Wellcome Found|Tablet|

---

GB9501142D0|1995-01-20|1995-03-08|Wellcome Found|Compounds for use in medicine|

---

DE19536164A1|1995-09-28|1997-04-03|Boehringer Ingelheim Kg|Improved Process for the Production of 9 - [ methyl] guanine |

---

EP0874631B1|1996-01-19|2003-11-19|Glaxo Group Limited|Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application|

---

US5756736A|1996-01-26|1998-05-26|SyntexInc.|Process for preparing a 2-methoxy-1,3-propanediol derivative|

---

US5840890A|1996-01-26|1998-11-24|SyntexInc.|Process for preparing a 2-methoxy-1,3-propanediol derivative|

---

DE69714971T3|1996-01-26|2005-12-15|F. Hoffmann-La Roche Ag|PROCESS FOR THE PREPARATION OF PURINE DERIVATIVES|

---

US5700936A|1996-01-26|1997-12-23|SyntexInc.|Process for preparing a 2- methoxy-1,3-propanediol valinate|

---

US6040446A|1996-01-26|2000-03-21|SyntexInc.|Process for preparing a 2- methoxy-1,3-propanediol derivative|

---

US5869493A|1996-02-16|1999-02-09|Medivir Ab|Acyclic nucleoside derivatives|

---

US6703394B2|1996-02-16|2004-03-09|Medivir Ab|Acyclic nucleoside derivatives|

---

IT1283447B1|1996-07-18|1998-04-21|Ind Chimica Srl|VALACICLOVIR PREPARATION PROCESS AND RELATED INTERMEDIATES|

---

EP0976750A4|1997-01-17|2001-05-30|Ajinomoto Kk|Novel z-valacyclovir crystals|

---

CA2332961A1|1998-05-21|1999-11-25|Michael Zasloff|A method for stimulation of defensin production by exposure to isoleucine|

---

IL160721D0|2001-09-07|2004-08-31|Teva Pharma|Crystalline forms of valacyclovir hydrochloride|

---

US20050043329A1|2002-09-06|2005-02-24|Shlomit Wizel|Crystalline forms of valacyclovir hydrochloride|

---

AU2003240213A1|2002-06-24|2004-01-06|Ranbaxy Laboratories Limited|Process for the preparation of robust formulations of valacyclovir hydrochloride tablets|

---

CN1309732C|2002-10-28|2007-04-11|南京长澳医药科技有限公司|Method for preparing 6-alkoxy-2',3'-double deoxidated guanosine|

---

US20050085491A1|2003-06-02|2005-04-21|Igor Lifshitz|Novel crystalline forms of valacyclovir hydrochloride|

---

CN1331471C|2003-09-22|2007-08-15|陈云芳|Combination of valaciclovir hydrochloride soft capsule|

---

US20050192296A1|2004-01-21|2005-09-01|Zvi Harel|Process for the preparation of valacyclovir hydrochloride|

---

GB2413017A|2004-04-06|2005-10-12|Ford Global Tech Llc|An electrical connector for a vehicle|

---

WO2006035452A1|2004-09-27|2006-04-06|Matrix Laboratories Ltd|Novel pseudomorph of valaciclovir hydrochloride|

---

WO2006127217A2|2005-05-25|2006-11-30|Eli Lilly And Company|Cyclopropanecarboxylate esters of acyclovir|

---

EP1746098A1|2005-07-21|2007-01-24|SOLMAG S.p.A.|Valacyclovir polymorphs and a process for the preparation thereof|

---

CN101456859B|2009-01-06|2011-07-20|华南理工大学|Method for preparing antiviral drug valaciclovir|

---

WO2011158252A1|2010-06-15|2011-12-22|Matrix Laboratories Ltd|Process for the preparation of valacyclovir hydrochloride polymorphic form ii|

---

CN102850354B|2012-10-10|2014-07-23|山东金城医药化工股份有限公司|Preparation method of high-purity carbamazepine -valaciclovir|

---

CN106632335A|2016-12-27|2017-05-10|河南康达制药有限公司|Preparation method of valaciclovir hydrochloride|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

GB878719367A|GB8719367D0|1987-08-15|1987-08-15|Therapeutic compounds|

---

GB878725939A|GB8725939D0|1987-11-05|1987-11-05|Therapeutic compounds|LV920335A| LV5264A3|1987-08-15|1992-12-18|Achievement of guanine derivatives or their pharmaceutically usable additive-additive|

---

LTRP270A| LT2063B|1987-08-15|1992-12-30|THE BUDGET FOR GUANINOUS WELL OR PHARMACEUTICAL USED SALTS|